Recent presentations

School of Medical Sciences Recent presentations

Hicks, K.O., Patel, K., Pruijn, F.B., Hay, M.P., Wilson, W.R. Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs. Proc Am Assoc Cancer Res. 2005, 46, 969.
Hay MP, Pruijn FB, Hicks KO, Pchalek K, Botting KJ, Hogg A, Petrovic-Stojanovska B, Liyanage HDS, Valentine SP, Siim BG, Denny WA, Wilson WR. Novel hypoxia-selective 3-alkyl-1,2,4-benzotriazine 1,4-dioxides with improved extravascular transport. Proc Am Assoc Cancer Res 2005;46.
Hicks KO, Patel K, Pruijn FB, Hay MP, Wilson WR. Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs. Proc Am Assoc Cancer Res 2005;46: 969.
Siim BG, Hay MP, Pruijn FB, Hicks KO, Pchalek K, Denny WA, Valentine SP, Fraser AM, Wilson WR. Hypoxia-selective 3-alkyl-1,2,4-benzotriazine 1,4-dioxide bioreductive drugs: analogues of tirapazamine with improved in vivo activity. Clin Cancer Res 2005;11: 8973s.
Wilson WR, Edmunds SJ, Valentine S, Gu Y, Myint H, Hicks KO, Yang S, Atwell GJ, Denny WA, Patterson AV. Mechanism of action and antitumour activity of PR-104, a dinitrobenzamide mustard pre-prodrug that is activated selectively under hypoxia. 2005;NCRI Conference October 2-5.
Hicks KO, Hay MP, Pruijn FB, Siim BG, Denny WA, Secomb TW, Dewhirst MW, Wilson WR. Using 3D pharmacokinetic/pharmacodynamic modelling for lead optimisation: selection of tirapazamine analogues for progression to in vivo testing. New Zealand Society for Oncology Conference 2004; June 24-26, 2004, Christshurch, New Zealand.
Pruijn FB, Hicks KO, Wilson WR. Prediction of drug diffusion coefficients in multicellular layers. A model for extravascular tumour transport. LogP2004 The 3rd Lipophilicity Symposium, February 29th to March 4th, Zürich, Switzerland 2004.
Wilson WR, Pullen SM, Degenkolbe A, Ferry DM, Helsby NA, Hicks KO, Atwell GJ, Yang S, Denny WA, Patterson AV. Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins. Eur J Cancer 2004; Suppl. 2(8): 151.
Hicks KO, Siim BG, Pruijn FB, Hsu R, Secomb TW, Dewhirst MW, Wilson WR. Modelling of tirapazamine distribution and cytotoxicity in one-dimension and in a mapped three-dimensional window chamber microvascular network: implications for analogue development. New Zealand Society for Oncology Conference 2003; April 30- May 2, 2003, Auckland, New Zealand.
Hicks KO, Siim BG, Pruijn FB, Hsu R, Secomb TW, Dewhirst MW, Wilson WR. Modeling of tirapazamine distribution and cytotoxicity in one-dimension and in a mapped three-dimensional window chamber microvascular network: implications for analogue development. Proc Am Assoc Cancer Res 2003;44: 906-7.
Wilson WR, Pruijn FB, Sturman JR, Degenkolbe A, Botting J, Liyanage HD, Patterson AV, Hay MP, Gamage S, Denny WA, Brown M, Hicks KO. Validation of the multicellular layer model as a tool for optimization of anticancer drugs: Extravascular transport properties determined in multilayers improve prediction of in vivo activity of tirapazamine analogs. Proc Am Assoc Cancer Res 2003;44: 909.
Hicks KO, Pruijn FB, Phua H-H, Sturman JR, Wilson WR. Foundations of a spatially-resolved pharmacokinetic/pharmacodynamic (PK/PD) model for the hypoxic cytotoxin tirapazamine. Proc Am Assoc Cancer Res 2002;43: 426-7.
Wilson WR, Ferry DM, Patterson AV, Pullen SM, Helsby NA, Pruijn FB, Hicks KO. Extravascular transport of GDEPT prodrugs in multicellular layer cultures: Dinitrobenzamide mustard substrates for the E. coli nitroreductase NTR. Proc Am Assoc Cancer Res 2002;43: 84-5.

SCHOOLS, DEPARTMENTS AND CENTRES

Apply now

Student Services Online

Download a prospectus

Postgraduate Fair 31 May 2012

Please give us your feedback or ask us a question